I suspect this is where a new way of doing things, which is already happening in oncology and other areas, called precision medicine could come into play.
So rather than defining disease by its phenotypic/syndromic features, it is defined by its molecular features. What this would mean, is that instead of having to do a separate trial for each of 100+ syndromes, you just do one trial incorporating any patient who has a genetic alteration resulting in IGF-1 and pERK dysregulation for example, or whatever the molecular target of 2591 is deemed to be.
Now this is all more easily said than done and is a nascent field, but it is already happening and with the exponential advances in the field of genomics I think provides a way forward for phenotypically heterogeneous disease.
- Forums
- ASX - By Stock
- Moonsoon Briefing Thurs 20 April
I suspect this is where a new way of doing things, which is...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.39 |
Change
-0.470(2.37%) |
Mkt cap ! $2.478B |
Open | High | Low | Value | Volume |
$19.70 | $19.77 | $19.28 | $10.38M | 534.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 2680 | $19.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.41 | 362 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 2680 | 19.350 |
1 | 1365 | 19.320 |
3 | 2436 | 19.310 |
2 | 4246 | 19.300 |
5 | 2474 | 19.290 |
Price($) | Vol. | No. |
---|---|---|
19.410 | 362 | 1 |
19.490 | 1365 | 1 |
19.500 | 24 | 1 |
19.520 | 1365 | 1 |
19.540 | 1180 | 2 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online